Cover Story

Features

  • How to survive the patent cliff

    This year $50 billion worth of drugs come off patent. The pharma industry’s response will be to focus on personalised medicine and biologics. Eileen McDermott explains how this will shift IP strategy towards trade secrets, data and patenting processes

  • Trade secrets and jurisdiction explained

    Benjamin Bai explains why a US decision that expands the jurisdiction of the ITC in trade secrets cases may be flawed, and contrasts it with the limited approach of the Supreme People’s Court in China

  • Tips on being social media counsel

    The in-house IP lawyer is often given responsibility for social media policy, even though many of the issues are nothing to do with IP infringement. Carmen Glatt and Kim Scallan give some advice on coping with the role

  • How to avoid filing catastrophes under the America Invents Act

    Jeremy Cubert and Eric Silverman introduce readers to Pharmville, USA, a futuristic community of inventors operating after full implementation of the America Invents Act

  • Who has the best IP tax regime?

    As the UK announces the details of its Patent Box, local lawyers from six jurisdictions in Europe explain how their tax incentives work and their relative successes

News Analysis

IP Clinic

News in Brief

Diary

Country Updates

More from the Managing IP blog


June 2013

The Madrid Protocol comes of age

India’s accession means the Madrid Protocol now covers more than two-thirds of the world’s population. Is this the tipping-point for the international trade mark system, and what reforms are needed? Emma Barraclough, James Nurton and Alli Pyrah report



Most read articles

Poll

Following the US Apple v Samsung trial, do you think juries should play a role in patent cases?







Supplements